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Early detection is the hallmark of successful cancer treatment. Evidence is accumulating that primary cancers begin 
shedding neoplastic cells into the circulation at an early stage. To date, many different methodologies have been 
used for the detection of circulating tumor cells (CTCs) with variable sensitivity and specificity. In many studies, 
including patients with different clinical stages of colorectal cancer, the detection of CTCs in early and/or metastatic 
colorectal cancer has been shown to correlate with unfavorable clinical outcome. However, a high-sensitivity and 
high-throughput method for the detection of CTCs is currently lacking. Here, we introduce a high-sensitivity genechip 
analysis method from a colorimetric membrane array to a weighted enzymatic chip array in order to detect the CTC-
related multiple mRNA markers derived from colorectal cancer patients as a convenient and practical tool for early 
diagnosis and prognosis prediction.
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Introduction
Colorectal cancer (CRC) is a significant public health 
problem.1 CRC is ranked fourth in incidence of all 
cancers for men, and third for women with approx-
imately 1 million new cases in 2002 (9.4% of the 
world total), and 529,000 deaths from CRC are re-
ported around the world annually.2 In Taiwan, CRC 
is one of the most common malignancies, and is 
the third leading cause of cancer-related death. 
The incidence of CRC in Taiwan was 35.06/100,000 
in 2004; gradually approaching Western figures in 
the last decade. In addition, more than 10,500 new 
cases of CRC were diagnosed, and more than 4,100 
Taiwanese died from CRC in 2007.3 There is a dra-
matic difference in survival rates between patients 
with early-stage CRC, and those with advanced 
stage CRC.4,5 Nineteen percent of patients with CRC 
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are diagnosed at an advanced stage, decreasing the 
5-year survival rate to 11%.6 Early diagnosis has the 
potential to decrease the morbidity and mortality 
of CRC patients.7 The preventable mortality rate 
highlights the need for improving accessibility and 
reliability of diagnosis of CRC at earlier stages.
Promising advances in image technology and other 
diagnostic modalities have been achieved recently, 
including radiological cross-sectional imaging, com-
puterized tomography (CT) and magnetic resonance 
imaging (MRI), and these methods meet the required 
sensitivity (capable of detecting tumor nodules of 
≥ 1 cm in diameter). However, the high financial cost 
and potentially unacceptable radiation exposures 
make usage for common screening a less likely pros-
pect.8,9 The relatively high false-positive rates of 
fecal occult blood tests and other invasive diagnos-
tic methods, such as double-contrast barium enemas, 
flexible sigmoidoscopy and colonoscopy, are unsuit-
able for broad screening due to the low general ac-
ceptance and highly-invasive nature.10−13 Hence, it is 
essential to develop a more reliable, relatively inex-
pensive, and non-invasive method for early diagnosis 
of CRC patients.
New Concept of Circulating Tumor 
Cells (CTCs)
CTCs are those cells present in blood circulation 
that possess antigenic and/or genetic characteris-
tics of a specific tumor type.14 CTCs are often de-
tected in the blood of cancer patients.15−17 It was 
reported by Weidner et al18 that active angiogen-
esis may occur in cancer tissues as little as 2 mm in 
diameter. Cumulative evidence indicates that pri-
mary cancers begin shedding neoplastic cells into 
the circulation at an early stage,19,20 and approxi-
mately 106 cells are shed daily per gram of tumor.21 
CTCs are a heterogeneous population of cells with 
biological characteristics, and often are different 
from those of their respective primary cell popula-
tions. Since early detection is one of the most effec-
tive means of reducing cancer mortality, CTCs are 
a potential source for the noninvasive and early di-
agnosis for cancer patients.22,23 Moreover, the ge-
netic and phenotypic profiling of CTCs often differs 
from that of the primary tumor, and could be used 
to select the most effective targeted therapy.24 
Consequently, the study of CTCs, apart from the 
impact on refining prognosis, has the exciting po-
tential of individualizing treatment strategies for 
cancer patients.
CTC characterization at different time points 
during the course of disease may provide useful 
predictive information for the selection of the most 
appropriate treatment(s). In 2005, Sher et al17 re-
ported that CTC could be a prognostic marker for 
non-small cell lung cancer and Yie et al25 indicated 
that the detection of survivin-expressing CTCs was 
found to be an independent predictor for cancer 
recurrence and survival in 2009. Therefore, CTC 
detection and characterization might become a valu-
able tool to refine prognosis, and serve as a real-
time tumor biopsy for individually tailored cancer 
therapy.13,23,26
Molecular Detection of CTC
Because CTCs are usually found at very low frequen-
cies among the normal peripheral blood, tumor cell 
enrichment techniques, including density gradient 
centrifugation (Ficoll-Hypaque separation), immu-
nomagnetic or size filtration procedures are often 
used to enrich tumor cells before their detection.27,28 
Molecular assays have generally been considered 
more sensitive, while immunocytochemistry has the 
advantage of allowing the morphological assess-
ment of stained cells.29,30 In the past decade, com-
monly used techniques for the detection of nucleic 
acid material of disseminated tumor cells included 
antibody-based assays (immunohistochemistry),31,32 
polymerase chain reaction, reverse-transcriptase 
PCR (RT-PCR), or real-time quantitative PCR (Q-PCR) 
assays, which are now possible by the sensitive de-
tection of CTCs in peripheral blood.16,33−35 These 
methods make it possible to detect minute quanti-
ties of a tumor-related molecular marker in the pe-
ripheral blood of patients with different types of 
early or advanced cancer. Stathopoulou et al36 have 
reported that detection of CK19 mRNA-positive cells 
by real-time RT-PCR assay as a surrogate for CTCs 
in women with early breast cancer. However, dis-
cordant results have been reported when different 
methodologies for CTC detection have been used. 
The lack of standardization of technology hampers 
the implementation of CTC measurement in routine 
clinical practice and clinical relevance of CTCs.
Despite the obvious and significant differences 
in CTC detection rates among molecular methods, 
one of the major limitations has been that the meth-
odology for molecular detection of CTCs may ana-
lyze only one molecular target per test.16,33−35 Due 
to the heterogeneity of specific gene marker ex-
pression in blood, a multimarker assay is regarded 
as more reliable and sensitive than a single-marker 
test.14,15,17,37 Hence, a panel of molecular markers 
would be necessary to increase the sensitivity of 
CTC detection.14 Therefore, well-standardized de-
tection methods for CTC-related multiple markers 
is strongly needed.
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Genechip Technique for Analyzing the 
CTC With Multiple mRNA Markers
For the detection of multiple targets or gene clus-
ters, the PCR-related techniques tend to have the 
disadvantages of being time-consuming, cumber-
some and costly. The rapid development of bio-
technology in recent years has made biochips an 
important tool in clinical diagnosis or drug efficacy 
evaluation.24
Although the results of Wang et al38 has showed 
that using RT-QPCR for the detection of CEA mRNA 
could be a promising tool for early detection of 
micrometastatic CTCs, but the detection of multi-
ple markers would be time wasted and laborious in 
applying RT-PCR for clinical practice. Therefore, a 
robust biochip assay for simultaneously detecting 
CTCs with an excellent high-sensitivity and high-
throughput quality is critical and it is imperative to 
use a panel of informative mRNA markers.
In order to develop the biochip assay for de-
tecting the CTC-related multimarkers from CRC pa-
tients for early diagnosis and prognosis prediction, 
first of all, it is necessary to identify the CRC-related 
mRNA markers suitable for CTC detection. In 2005, 
Wang et al39 have analyzed differently expressed 
genes between tumor tissue and normal tissue of 
CRC patients by using cDNA microarrays. The iden-
tification of differently expressed genes has im-
portant implications in understanding the biology 
of CRC, as well as identifying new diagnostic and 
therapeutic strategies. In that study, cDNA micro-
array technology was used to identify colorectal 
tumor-related functional genes, which were over-
expressed continuously from colorectal adenoma to 
adenocarcinoma. A set of 23 genes which has been 
protected by the pattern was identified by cDNA 
microarray, and confirmed by direct sequencing 
and Northern blot analysis. Among the 23 genes, 22 
function-known genes were involved in cell motility, 
cell adhesion, chemokine activity, signal transduc-
tion, cytoskeleton organization, proteolysis, apo-
ptosis, and cell proliferation. The genes which were 
identified in the study offer valuable information on 
colorectal carcinogenesis and metastasis, and rep-
resent a potential source of novel targets for new 
strategies for CRC diagnosis.
In 2006, Yeh et al40 have evaluated the simulta-
neous detection of multiple mRNA markers by using 
a colorimetric membrane array (CLMA) in the pe-
ripheral blood of CRC patients for early diagnosis. 
Twenty-seven tumor tissue specimens and 80 pe-
ripheral blood specimens were collected from CRC 
patients. First, the mRNA levels of multiple molec-
ular markers, including CK-19, CK-20, CEA, REG4, 
uPA, and TIAM1 mRNA in the tumor tissue and blood 
specimens, were evaluated by using RT-QPCR and 
membrane array. Among the 80 patients, the over-
expression of CK-19 (82.5%), CK-20 (78.8%), CEA 
(82.5%), REG4 (80.0%), uPA (78.8%), and TIAM1 mRNA 
(80.0%) were detected by RT-QPCR and membrane 
array, indicating consistent results compared to 
each other, and had a high degree of correlation 
(r = 0.954, p < 0.0001). Then, a CRC diagnostic gene-
chip was constructed including six markers for further 
clinical evaluation. The sensitivity (88.8%), specifi-
city (87.8%), and accuracy (88.2%) of a membrane 
array-based diagnostic method with multiple mark-
ers for CRC diagnosis were much higher than those 
of evaluations with single marker.40 The results of 
those studies had shown that the innovative gene-
chip technique with multiple mRNA markers could 
significantly improve the clinical diagnosis of early 
colorectal cancer.
The photo-chart of the genechip technique is 
shown in Figure 1. Identified CRC-related oligonu-
cleotides were synthesized and spotted on a nylon 
membrane to construct a CRC diagnostic genechip. 
Digoxigenin (DIG)-labeled cDNAs were amplified by 
RT-PCR from the peripheral blood of CRC patients, 
and were hybridized to the genechip. Hybridization 
signals were detected by color development. 
According to the figure, we would realize not only 
the whole process of CTC-related mRNA markers as 
detected by genechip, but also the technique ana-
lyzed for early diagnosis of CRC patients.
Development of Genechip 
Operation Platform
Since 2005, Chen et al22 has successfully constructed 
mutational KRAS detection genechips to detect the 
KRAS oncogene by membrane array with high sen-
sitivity (83.7%) and specificity (90.9%). The findings 
suggested that the genechip devised for mutant KRAS 
detection has a great potential for further investi-
gation and clinical application. Moreover, in 2006, 
Wang et al41 developed a high-sensitivity colorimet-
ric membrane-array method to detect CTCs for early 
diagnosis in the peripheral blood of CRC patients 
as a potential diagnostic tool, and demonstrated 
a significantly high correlation between real-time 
Q-PCR and the membrane array method in the de-
tection of CTCs. The results of CLMA were demon-
strated to be closely related to that of Q-PCR 
(p < 0.001), and the sensitivity and specificity of the 
colorimetric membrane array for the detection of 
CTCs were 94.3% (95% confidence interval [CI], 86.4−
102.2%) and 94% (95% CI, 85.9−102.1%), respec-
tively.41 The CLMA for detecting CTC-related multiple 
mRNA markers from the peripheral blood of CRC 
patients, not only could be used for early cancer 
diagnosis, but also would be considered a rational 
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approach for the postoperative surveillance of CRC 
patients.22,40−42 Furthermore, the accuracy of CLMA 
for detecting multiple biomarkers is higher than that 
of any one gene detected by Q-PCR. The results indi-
cated that the accuracy of CLMA data was sufficient 
to distinguish Taiwanese CRC patients from normal 
individuals with the advantages of time-saving, cost-
effectiveness and high-throughput. Although the 
CLMA could be a promising approach for the clinical 
detection of CTCs in CRC patients, the sensitivity, 
specificity, and accuracy of the method still needed 
optimization.
Each gene on the genechip was calculated with 
the same value while the outcome interpreted by 
CLMA. This does not differentiate the importance 
of each gene for specific disease prognosis, which 
is a major limitation of CLMA in clinical applica-
tion.43 In addition, the cost of the digoxigenin en-
zyme used on the CLMA platform was too expensive 
for laboratory diagnosis, and the operating tech-
niques too skill-intensive for widespread clinical 
applications. Therefore, Hsiung et al44 developed 
the new generation genechip operation platform, 
which replaced the conventional digoxigenin sys-
tem by the bioton-avidin enzyme, as a first step to 
lower the cost of analysis. Furthermore, the au-
thors weighted multiples for each target gene on 
the same genechip during the cancer development 
process to improve the accuracy of CTC detection, 
and established a new weighted enzymatic chip 
array (WEnCA) platform.
After the manual operation platform including 
CLMA and WEnCA had been successfully established 
and published,45 an automatic system of WEnCA-
Chipball developed by fluid engineering was further 
established to effectively reduce the manual errors 
and limitations due to technical criteria.44 Figure 2 
shows the operation platform including CLMA, 
WEnCA-manual and WEnCA-Chipball.
In order to understand the actual differences be-
tween the operations of WEnCA-Chipball and WEnCA-
manual, Hsiung et al41 have used the WEnCA-manual 
to analyze KRAS-associated gene overexpression in 
200 samples from cancer patients to establish a cut-
off-value for the Activated KRAS Detection Chip. 
Specifically, the activated KRAS expressions in blood 
samples of 209 lung cancer patients were analyzed 
by both WEnCA-manual and WEnCA-Chipball. The 
clinical applicability of WEnCA-Chipball was de-
fined, including the sensitivity, specificity and the 
accuracy. The results showed that, among 209 sam-
ples, 71 of the patients were positive on activated 
KRAS expression with high sensitivity (89%), spe-
cificity (94%), and accuracy (92%). In addition, the 
average total score of WEnCA-Chipball was 4.7 
lower than that of the WEnCA-manual procedure. 
The WEnCA-Chipball required an operation time of 
only 7.5 hours, which was approximately one ninth 
Figure 1 Detection of circulating tumor cells (CTC)-related mRNA markers by genechip.
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of the WEnCA-manual operation time, and one fifth 
of the cost of WEnCA-manual procedure. No signifi-
cant difference was found between the detection 
limitations of the two systems. Hence, great strides 
have been made in this system development, with 
the potential of the WEnCA-Chipball operation sys-
tem being used for clinical applications.44
Application of CTC Detection by 
Genechip for CRC
In 2006, Wang et al38 used RT-PCR to detect 
human telomerase reverse transcriptase (hTERT), 
cytokeratin-19 (CK-19), cytokeratin-20 (CK-20), and 
CEA mRNA in the peripheral blood of 72 CRC patients 
and 30 healthy individuals for CTCs detection. The 
results showed that using RT-PCR for the detection 
of CEA mRNA is feasible and may be a promising 
tool for early detection of micrometastatic CTCs in 
CRC patients. For advanced-stage disease, the avail-
ability of CTCs may allow for better disease moni-
toring, especially in patients with metastatic CRC 
(mCRC) who do not have any measurable increase 
in CEA or other known markers. Using a colorimet-
ric membrane array method, Wang et al42 detected 
CTCs in peripheral blood of 157 postoperative CRC 
patients with normal perioperative serum CEA lev-
els, found the expression of all 4 mRNA markers 
(hTERT, CK-19, CK-20, and CEA mRNA) was an inde-
pendent predictor for postoperative CRC relapse. 
The CRC patients with all 4 mRNA markers expres-
sion showed a significantly poorer survival rate than 
those with less than four positive markers. Moreover, 
the high-sensitivity CLMA method has been evaluated 
as a potential diagnostic and postoperative surveil-
lance tool to detect CTCs through the 4 mRNA mark-
ers in the peripheral blood of CRC patients with 
normal perioperative serum CEA levels.42
Adjuvant chemotherapy is not routinely recom-
mended in patients diagnosed with UICC stage II 
CRC. However, up to 30% of patients with stage II CRC 
relapse within 5 years of surgery from recurrent or 
metastatic disease. The identification of reliable 
prognostic factors for high-risk stage II CRC patients 
is imperative. In 2007, Uen et al46 constructed a 
genechip consisting of a panel of mRNA markers 
(including hTERT, CK-19, CK-20, and CEA mRNA) to 
detect CTCs in the peripheral blood of 194 stage II 
CRC patients by CLMA, to identify a subgroup of 
patients who are at high risk for relapse. The study 
results showed that the postoperative relapse was 
significantly correlated with the depth of invasion 
(p < 0.001), the presence of vascular invasion (p < 
0.001), the presence of perineural invasion (p = 0.048), 
the expression of all 4 mRNA markers (p < 0.001), and 
the number of examined lymph nodes (p = 0.031). 
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Figure 2 Genechip operation platform. CLMA: colorimetric membrane array; WEnCA: weighted enzymatic chip array.
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CRC patients underwent curative resection and 
found the persistent presence of CTCs was strongly 
correlated with poorer relapse-free survival rates 
(all p < 0.001). Therefore, the genechip method of 
CTCs detection is a potential auxiliary tool to con-
ventional clinicopathological variables for the pre-
diction of postoperative relapse in stage II CRC 
patients.46
Furthermore, these methods could be used to 
identify subgroups of patients who would benefit 
from adjuvant therapy. It had been underscored 
within the past decade in CRC by patient response 
to cetuximab is at least partially determined by 
KRAS mutational status of the tumor.48 By the high-
throughput gene expression array method, the de-
tection of KRAS mutations have been recently 
applied in the clinic to mCRC patients treated with 
Cetuximab and FOLFOX4 (oxaliplatin plus leucov-
orin plus fluorouracil) or FOLFIRI (leucovorin plus 
fluorouracil plus irinotecan).22,49 Among 76 meta-
static colorectal cancer patients, KRAS mutations 
in tumors and in peripheral blood were identified 
Table 1  Genechip technique for early diagnosis and prognosis prediction of colorectal cancer (CRC) patients by 
detecting circulating tumor cells (CTC)-related mRNA markers22,40−42,44,46,47,49−54
  Genechip 
CTC-related mRNA
 
Study Year operation  Conclusion
  platform 
markers
Chen et al22 2005 CLMA KRAS pathway related Membrane array has a great
   molecular markers potential for KRAS oncogene detection in CTC
Yeh et al40 2006 CLMA CK19, CK20, CEA, REG4,  Membrane array can significantly 
   UPA, TIAM1 improve the diagnosis rate of early CRC
Wang et al41 2006 CLMA CRC-related biomarkers  Membrane array was sufficient to 
distinguish Taiwanese CRC patients with 
advantages of time-saving, cost-effectiveness 
and high throughput
Wang et al42 2007 CLMA hTERT, CK19, CK20, CEA  Membrane array helpful in the early 
prediction of postoperative relapse in 
CRC patients with normal CEA level
Uen et al46 2007 CLMA hTERT, CK19, CK20, CEA  Membrane array is a potential auxiliary 
tool for predicting the postoperative 
relapse in stage II CRC patients who 
have undergone curative resection
Yeh et al50 2008 CLMA Glycolytic pathway Glycolytic pathway and glycolysis
   related markers  related genes may play an important role in 
the tumorigenesis of CRC
Uen et al47 2008 CLMA hTERT, CK19, CK20, CEA  Persistent presence of CTCs were demonstrated
to be independent predictor for postoperative
relapse in stage I−III CRC patients
Chung et al51 2009 CLMA Hypoxia related markers  GLUT1 has the potential to be the molecular 
marker for indicating the degree of hypoxia in 
CRC patient
Yen et al49 2009 CLMA KRAS pathway related Activated KRAS mutants is an utmost important 
   molecular markers  independent predictive marker in metastatic 
CRC patient treated with cetaximab plus 
chemotherapy
Hsiung et al44 2009 WEnCA-Chipball KRAS pathway related WEnCA-Chipball has great potential for CTCs
   molecular markers detection in clinical application
Huang et al52 2010 CLMA MMP13 MMP13 is a potential prognostic marker for CRC
Chung et al53 2010 CLMA MAGE family genes  MAGE A2, B3, D2, H1 are correlated to 
carcinogenesis of CRC 
Hsiung et al54 2011 WEnCA-Chipball KRAS pathway related WEnCA-Chipball retains the advantages of the
   molecular markers  Lab-om-a-chip and also overcomes the problem 
of the unsuitability of the microfluidic chip for 
continuous operation
CLMA: colorimetric membrane array; WEnCA: weighted enzymatic chip array.
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respectively in 33 (43.4%) and 30 (39.5%) patients. 
The detection sensitivity, specificity, and accuracy 
of genechip for CTCs with KRAS oncogene respec-
tively, were 84.4%, 95.3%, and 90.8%, and that a 
highly significant correlation to KRAS mutations in 
tumors (p < 0.0001) was observed. Similarly, patients 
with CTCs of wild-type KRAS in peripheral blood 
express a better progression-free survival and over-
all survival when treated with cetuximab plus chemo-
therapy (p < 0.0001).49 These findings indicate that 
the detection of KRAS mutational status in CTCs by 
genechip has potential for clinical application in 
selecting mCRC patients who probably would ben-
efit from cetuximab therapy.
Conclusions
From studies summarized in Table 1,22,40−42,44,46,47,49−54 
the genechip technique including CLMA, WEnCA-
manual and automatic operation platform—WEnCA-
Chipball are all reliable tools for early diagnosis 
and prognosis prediction of CRC patient by detec-
tion CTC-related mRNA markers. These results also 
highlight the need for prompt further studies on a 
larger number of CRC patients in order to validate 
and standardize genechip testing procedures prior 
to use in clinical practice.
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